All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
27 results for "Cancer" and "Gynecologic Cancers" and "Lymphoma"
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti0CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Sub Category
A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL
Protocol No
SWOG-S1826-HL
Sub Category
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase 1, First-in-Human clinical trial, meaning that it is the first study where TNB-486 will be given to humans. This study is open-label, meaning that everyone on the study will receive study drug, at various doses.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-cell Lymphoma
Split-Dose R-CHOP for Older Adults with DLBCL
Protocol No
WON-SHAH-UW18131-SPLIT-RCHOP
Sub Category
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
Protocol No
IIT-ABEDIN-NEIHULIZUMAB
Sub Category
A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)
Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease
Protocol No
ABGENOMICS-2017-002-01
Sub Category
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Sub Category
A randomized 3-arm Phase II study comparing 1) Bendamustine, Rituximab and high dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, high dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in patients </= 70 years old with untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
Randomized Phase II/III Study Of Venetoclax (Abt 199) Plus Chemoimmunotherapy For Myc/Bcl2 Double-Hit And Double Expressing Lymphomas
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Protocol No
ALLIANCE-A051701-DLBCL
Sub Category
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation in Older Adults
Composite Health Assessment Risk Model (CHARM) for Older Adults
Protocol No
CTN-1704
Sub Category
A Phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCL (EVOMELA®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
EVOMELA In Combination With Fludarabine and TBI based reduced intensity conditioning for Haplo BMT
Protocol No
IIT-HAMADANI-FLU-MEL-TBI
Sub Category
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after AlloHCT
Protocol No
DF-HCC-18-265-BOS
Sub Category
Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic BMT
Protocol No
CTN-1702
Sub Category
A Phase II, Single-Arm, Open-label Study of Itacitinib, for the prevention of cytokine Release Syndrome (CRS) induced by Immune Effector Cell Therapy
A study of Itacitinib for the Prevention of CRS induced by Immune Effector Cell Therapy
Protocol No
INCYTE-INCB-39110-211-CRS
Sub Category
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
YTB323 (CD19-specific CAR-T Cells) in patients with CLL/SLL and DLBCL
Protocol No
NOVARTIS-YTB323A12101
Sub Category
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With R/R DLBCL
Protocol No
ALLIANCE-A051301-CTN1201
Sub Category
MolecularTemplates-MT-3724: Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL (MT-3724-NHL-001)
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)
Protocol No
MOLECULARTEMPLATES-MT-3724-NHL
Sub Category
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Protocol No
ECOG-EA4151
Sub Category
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Tidrakizumab for Prevention of Acute Graft-Versus-Host Disease
Protocol No
IIT-RUNAAS-TILDRAKIZUMAB-AGVHD
Sub Category